EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacological Profiles and Recovery Predictors in Severe COVID-19

Heru Wijono, Fauna Herawati, Abdul Kadir Jaelani, Stefani Kartika Octavia, Dewi Ramdani, Nur Palestin Ayumuyas, Azminah, Kevin Kantono, Rika Yulia

COVID · 10.06.2026 · 6 (6) · 103

DOI: 10.3390/covid6060103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift COVID, online erschienen am 10.06.2026. Verfasst von Heru Wijono und 8 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Indonesian Ministry of Research, Technology and Higher Education.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study analyses the pharmacological profiles of medications administered to critically ill COVID-19 patients to evaluate their efficacy regarding recovery rates and duration of hospitalization. The results demonstrate a significant difference in clinical outcomes. While the administration of Ceftazidime, Ceftriaxone, and Oseltamivir was associated with negative survival trends, Dexamethasone and Favipiravir were associated with a fourfold higher probability of survival in severe cases. Notably, no pharmacological intervention significantly reduced the length of hospital stay; instead, recovery duration was primarily influenced by comorbidities such as obesity, cardiovascular disease, and diabetes. Furthermore, age and preexisting physiological conditions remained primary predictors of mortality. Observational analysis in our study for drug repurposing identified Amikacin, Remdesivir, and Rivaroxaban as potential therapeutic candidates. However, Dexamethasone was identified as the most effective treatment for recovery, likely due to a molecular structure with high potential binding affinity to the SARS-CoV-2 virus. These findings suggest that while specific repurposed drugs offer measurable benefits, patient history remains a critical determinant of outcomes, highlighting the necessity for further research to refine therapies against emerging viral pathogens.

Förderung

  • Indonesian Ministry of Research, Technology and Higher Education

Zitieren

APA

Wijono, H., Herawati, F., Jaelani, A. K., Octavia, S. K., Ramdani, D., Ayumuyas, N. P., Azminah, Kantono, K., & Yulia, R. (2026). Pharmacological Profiles and Recovery Predictors in Severe COVID-19. COVID, 6(6), 103. https://doi.org/10.3390/covid6060103

Vancouver

Wijono H, Herawati F, Jaelani AK, Octavia SK, Ramdani D, Ayumuyas NP, et al. Pharmacological Profiles and Recovery Predictors in Severe COVID-19. COVID. 2026;6(6):103. doi:10.3390/covid6060103

BibTeX
@article{Wijono2026,
  author = {Wijono, Heru and Herawati, Fauna and Jaelani, Abdul Kadir and Octavia, Stefani Kartika and Ramdani, Dewi and Ayumuyas, Nur Palestin and Azminah and Kantono, Kevin and Yulia, Rika},
  title = {Pharmacological Profiles and Recovery Predictors in Severe COVID-19},
  journal = {COVID},
  year = {2026},
  volume = {6},
  number = {6},
  pages = {103},
  doi = {10.3390/covid6060103}
}
Kostenlos starten →